P-202: Characterization of ocular adverse events in patients receiving Belantamab Mafadotin for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory Multiple Myeloma
Year: 2021
Type: conference-abstract
Authors: Sagar Lonial, Ajay Nooka, Praneetha Thulasi, Ashraf Z. Badros, Bennie Jeng, Natalie S. Callander, Douglas Sborov, Brian E. Zaugg, Rakesh Popat, Simona Degli Esposti, January Baron, Allison Doherty, Eric Lewis, Joanna Opalinska, Prani Paka, Trisha Piontek, Ira Gupta, Asim V. Farooq, Andrzej Jakubowiak
Institutions: Emory University, Winship Cancer Institute, Emory University Hospital, Emory Eye Center, University of Maryland Medical Center, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Huntsman Cancer Institute, University of Utah, University College London Hospitals NHS Foundation Trust, Moorfields Eye Hospital NHS Foundation Trust, GlaxoSmithKline (United States), University of Chicago Medical Center, University of Chicago
Language: English
Topic: Drug-Induced Ocular Toxicity
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4205759708